Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676365 | 1.00 | MAOA (0.45) | MAOAMAOBNOTUMHTR2AHTR2C | |
| SCHEMBL8176395 | 0.85 | MAOA (0.40) | MAOAMAOBHTR2AMAPK1SMN1; SMN2 | |
| SCHEMBL10957365 | 0.81 | MAPK1 (0.42) | MAOAMAOBMAPK1SMN1; SMN2DRD1 | |
| SCHEMBL12935341 | 0.80 | MAOA (0.45) | MAOAMAOBMAPK1SMN1; SMN2DRD2 | |
| SCHEMBL2625759 | 0.79 | MEN1 (0.39) | NOTUMHTR2AHTR2CHTR2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10954390 | 0.79 | MAOA (0.44) | MAOAMAOBMAPK1SMN1; SMN2DRD1 | |
| SCHEMBL17383970 | 0.78 | MAOA (0.48) | MAOAMAOBNOTUMDRD2DRD1 | |
| SCHEMBL13068444 | 0.78 | HTR2A (0.40) | NOTUMHTR2AHTR2CHTR2B | |
| SCHEMBL29391669 | 0.78 | MAOA (0.48) | MAOAMAOBNOTUMDRD2DRD1 | |
| SCHEMBL15345114 | 0.78 | MAOA (0.44) | MAOAMAOBMAPK1SMN1; SMN2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2062889-A1 | Compounds | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | MAOA 875/4885MAOB 818/4885NOTUM 3793/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885NOTUM 448/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | MAOA 4170/4885MAOB 4266/4885NOTUM 366/4885 |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BDKRB2, CALCR, CALCRL | MAOA 1381/4885MAOB 780/4885NOTUM 573/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | MAOA 4339/4885MAOB 3867/4885NOTUM 3251/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | MAOA 4713/4885MAOB 4254/4885NOTUM 4588/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | MAOA 700/4885MAOB 702/4885NOTUM 3226/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885NOTUM 448/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | MAOA 3856/4885MAOB 3037/4885NOTUM 489/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | MAOA 4694/4885MAOB 4531/4885NOTUM 4288/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | MAOA 4706/4885MAOB 4353/4885NOTUM 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.